Short Bowel Syndrome (SBS) Market to Observe Stupendous Growth During the Study Period (2020-2034) – DelveInsight | 9 Meters Biopharma, Surrozen, Takeda, Adocia, VectivBio, Zealand Pharma, Hanmi Pharma

February 21 18:49 2024
Short Bowel Syndrome (SBS) Market to Observe Stupendous Growth During the Study Period (2020-2034) - DelveInsight | 9 Meters Biopharma, Surrozen, Takeda, Adocia, VectivBio, Zealand Pharma, Hanmi Pharma
Delveinsight Business Research LLP
The Short Bowel Syndrome Market is set to register immense growth in the coming years owing to the increasing prevalence of SBS and the launch of new therapies in the market. Key players, such as Zealand Pharma, PhaseBio Pharmaceuticals, VectivBio, and several others, are involved in developing therapies for treating SBS patients.

DelveInsight’s “Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Short Bowel Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Short Bowel Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current Short Bowel Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Short Bowel Syndrome: An Overview

Short Bowel Syndrome is a congenital or acquired condition affecting the small intestine, hallmarked by loss of intestinal absorptive capacity with resultant malabsorption, dehydration, and malnutrition. This is due to the loss of absorptive surface area, as the human intestinal tract requires a massive surface area to absorb nutrients to support a growing and living organism effectively.

Short Bowel Syndrome is a challenging condition associated with significant morbidity and mortality, reduced quality of life, and high health care costs. In patients with Short Bowel Syndrome who are receiving long-term home parenteral nutrition (PN), 2–5 years survival rates have been reported to be up to 80% and 70%, respectively. Factors affecting survival with Short Bowel Syndrome include the anatomy and function of the remaining bowel, the patient’s age, the primary disease process, comorbid diseases, the presence of chronic intestinal obstruction, and the experience of the management team.

Short Bowel Syndrome Market Key Facts

  • The market size of Short Bowel Syndrome in the seven major markets was USD 1720.5 million in 2020, and the market is estimated to increase at a CAGR of 5.82% for the study period (2018–2030).
  • The total 7MM prevalent cases of Short Bowel Syndrome were 34,713 cases in 2020.
  • As per the data published by the Crohn’s & Colitis Foundation of America, approximately 10,000–20,000 people suffer from Short Bowel Syndrome in the United States.
  • As per the study conducted by Websky et al., titled “Short bowel syndrome in Germany. Estimated prevalence and standard of care”, the prevalence of SBS in Germany is 34 per million inhabitants.
  • According to the American Pediatric Surgical Association, the most common cause of SBS in infants and babies is necrotizing enterocolitis (NEC) which accounts for up to 40% of SBS patients.
  • According to the European Medicines Agency, SBS affects not more than 0.35 in 10,000 people in the European Union (EU).
  • As per the data published in PINNT, It is estimated that up to 1,000 people in England have short bowel syndrome, requiring long-term treatment with parenteral nutrition support.

Short Bowel Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Short Bowel Syndrome pipeline therapies. It also thoroughly assesses the Short Bowel Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Short Bowel Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Short Bowel Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Short Bowel Syndrome epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted Short Bowel Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Short Bowel Syndrome Epidemiology, Segmented as –

  • Total Prevalent Cases of Short Bowel Syndrome in the 7MM
  • Diagnosed and Treatable Cases of Short Bowel Syndrome in the 7MM

Short Bowel Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Short Bowel Syndrome market or expected to be launched during the study period. The analysis covers the Short Bowel Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Short Bowel Syndrome drugs based on their sale and market share.

The report also covers the Short Bowel Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Short Bowel Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Short Bowel Syndrome Market Will Evolve and Grow In the Upcoming Years @ 

https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

Short Bowel Syndrome Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Short Bowel Syndrome. Currently, Zealand Pharma is leading the therapeutics market with its Short Bowel Syndrome drug candidates in the most advanced stage of clinical development.

Short Bowel Syndrome Companies Actively Working in the Therapeutics Market Include

  • 9 Meters Biopharma
  • Adocia
  • Hanmi Pharmaceutical
  • NorthSea Therapeutics
  • PhaseBio Pharmaceuticals
  • Surrozen
  • Takeda
  • VectivBio AG
  • Zealand Pharma

And many others

Emerging and Marketed Short Bowel Syndrome Therapies Covered in the Report Include:

  • Glepaglutide: Zealand Pharma
  • Gattex (teduglutide): NPS Pharmaceuticals (Acquired by Shire Plc.)
  • Apraglutide: VectivBio/Therachon AG
  • NM 002: 9 Meters Biopharma

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Short Bowel Syndrome Competitive Intelligence Analysis

4. Short Bowel Syndrome Market Overview at a Glance

5. Short Bowel Syndrome Disease Background and Overview

6. Short Bowel Syndrome Patient Journey

7. Short Bowel Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Short Bowel Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Short Bowel Syndrome Unmet Needs

10. Key Endpoints of Short Bowel Syndrome Treatment

11. Short Bowel Syndrome Marketed Therapies

12. Short Bowel Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Short Bowel Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Short Bowel Syndrome Market Outlook (In US, EU5, and Japan)

16. Short Bowel Syndrome Companies Active in the Market

17. Short Bowel Syndrome Access and Reimbursement Overview

18. KOL Views on the Short Bowel Syndrome Market

19. Short Bowel Syndrome Market Drivers

20. Short Bowel Syndrome Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hidradenitis Suppurativa Market

“Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hidradenitis Suppurativa market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices